AGN-229666 for the Treatment of Allergic Conjunctivitis
NCT ID: NCT01754766
Last Updated: 2014-02-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
90 participants
INTERVENTIONAL
2012-10-31
2013-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis
NCT02082262
AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis
NCT02161146
AL-15469A for the Treatment of Bacterial Conjunctivitis
NCT00331916
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
NCT02965846
Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
NCT02978183
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AGN-229666 Dose A
One drop of AGN-229666 Dose A into each eye on Day 1 and Day 15.
AGN-229666
One drop of AGN-229666 into each eye on Day 1 and Day 15.
AGN-229666 Dose B
One drop of AGN-229666 Dose B into each eye on Day 1 and Day 15.
AGN-229666
One drop of AGN-229666 into each eye on Day 1 and Day 15.
vehicle of AGN-229666
One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
vehicle of AGN-229666
One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AGN-229666
One drop of AGN-229666 into each eye on Day 1 and Day 15.
vehicle of AGN-229666
One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to discontinue wearing contact lenses during the study period
Exclusion Criteria
* Presence of active eye infection (bacterial, viral, or fungal)
* History of an ocular herpetic infection
* Eye surgery intervention within 3 months and/or a history of refractive surgery within the past 6 months
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
229666-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.